运用倾向性评分的方法探讨联合使用灯盏细辛注射液对冠心病患者临床结局的影响(3)
Exploration of clinical outcomes on coronary heart disease of parenterally
administered Dengzhan Xixin using propensity score
SHEN Hao1， YANG Wei1， XIE Yan-ming1*， ZENG Xian-bin2
(1.Institute of Basic Research in Clinical Medicine， China Academy of Chinese Medical Science， Beijing 100700， China；
2. College of Statistics， Renmin University of China， Beijing 100872， China)
[Abstract] Parenterally administered Dengzhan Xixin is a common parenterally administered Chinese medicine for the treatment of coronary heart disease. The present research explored the application of parenterally administered Dengzhan Xixin on the clinical outcome of coronary disease. Hospital information system (HIS) data from 18 national， general hospitals was collected. Patients given parenterally administered Dengzhan Xixin in addition to other medications were compared with those not receiving it. General boosted method (GBM) and propensity score weighting was used to control for confounding variables between the groups. Logistic regression， and concomitant variable logistic regression of propensity score weighting were used to analyze the balanced confounding variable. Results showed that there was a statistically significant difference between the groups in death rate. The combined application of parenterally administered Dengzhan Xixin can lower the death rate from coronary disease. However， there are still a large amount of unknown confounding variable to take into account and the present research is a retrospective study. Therefore， prospective studies are warranted.
[Key words] parenterally administered Dengzhan Xixin； coronary heart disease； propensity score； mortality rate； real world research
doi：10.4268/cjcmm20131843, 百拇医药(申浩 杨伟 谢雁鸣 曾宪斌)
administered Dengzhan Xixin using propensity score
SHEN Hao1， YANG Wei1， XIE Yan-ming1*， ZENG Xian-bin2
(1.Institute of Basic Research in Clinical Medicine， China Academy of Chinese Medical Science， Beijing 100700， China；
2. College of Statistics， Renmin University of China， Beijing 100872， China)
[Abstract] Parenterally administered Dengzhan Xixin is a common parenterally administered Chinese medicine for the treatment of coronary heart disease. The present research explored the application of parenterally administered Dengzhan Xixin on the clinical outcome of coronary disease. Hospital information system (HIS) data from 18 national， general hospitals was collected. Patients given parenterally administered Dengzhan Xixin in addition to other medications were compared with those not receiving it. General boosted method (GBM) and propensity score weighting was used to control for confounding variables between the groups. Logistic regression， and concomitant variable logistic regression of propensity score weighting were used to analyze the balanced confounding variable. Results showed that there was a statistically significant difference between the groups in death rate. The combined application of parenterally administered Dengzhan Xixin can lower the death rate from coronary disease. However， there are still a large amount of unknown confounding variable to take into account and the present research is a retrospective study. Therefore， prospective studies are warranted.
[Key words] parenterally administered Dengzhan Xixin； coronary heart disease； propensity score； mortality rate； real world research
doi：10.4268/cjcmm20131843, 百拇医药(申浩 杨伟 谢雁鸣 曾宪斌)